378 related articles for article (PubMed ID: 19226371)
1. On the relationship between the two branches of the kynurenine pathway in the rat brain in vivo.
Amori L; Guidetti P; Pellicciari R; Kajii Y; Schwarcz R
J Neurochem; 2009 Apr; 109(2):316-25. PubMed ID: 19226371
[TBL] [Abstract][Full Text] [Related]
2. Perinatal kynurenine 3-hydroxylase inhibition in rodents: pathophysiological implications.
Ceresoli-Borroni G; Guidetti P; Amori L; Pellicciari R; Schwarcz R
J Neurosci Res; 2007 Mar; 85(4):845-54. PubMed ID: 17279543
[TBL] [Abstract][Full Text] [Related]
3. Metabolism of [5-(3)H]kynurenine in the developing rat brain in vivo: effect of intrastriatal ibotenate injections.
Ceresoli G; Guidetti P; Schwarcz R
Brain Res Dev Brain Res; 1997 May; 100(1):73-81. PubMed ID: 9174248
[TBL] [Abstract][Full Text] [Related]
4. Activation of the kynurenine pathway and increased production of the excitotoxin quinolinic acid following traumatic brain injury in humans.
Yan EB; Frugier T; Lim CK; Heng B; Sundaram G; Tan M; Rosenfeld JV; Walker DW; Guillemin GJ; Morganti-Kossmann MC
J Neuroinflammation; 2015 May; 12():110. PubMed ID: 26025142
[TBL] [Abstract][Full Text] [Related]
5. Kynurenine 3-Monooxygenase Activity in Human Primary Neurons and Effect on Cellular Bioenergetics Identifies New Neurotoxic Mechanisms.
Castellano-Gonzalez G; Jacobs KR; Don E; Cole NJ; Adams S; Lim CK; Lovejoy DB; Guillemin GJ
Neurotox Res; 2019 Apr; 35(3):530-541. PubMed ID: 30666558
[TBL] [Abstract][Full Text] [Related]
6. Assessment of Prenatal Kynurenine Metabolism Using Tissue Slices: Focus on the Neosynthesis of Kynurenic Acid in Mice.
Notarangelo FM; Beggiato S; Schwarcz R
Dev Neurosci; 2019; 41(1-2):102-111. PubMed ID: 31117076
[TBL] [Abstract][Full Text] [Related]
7. Targeting kynurenine 3-monooxygenase (KMO): implications for therapy in Huntington's disease.
Thevandavakkam MA; Schwarcz R; Muchowski PJ; Giorgini F
CNS Neurol Disord Drug Targets; 2010 Dec; 9(6):791-800. PubMed ID: 20942784
[TBL] [Abstract][Full Text] [Related]
8. L-Tryptophan-kynurenine pathway enzymes are therapeutic target for neuropsychiatric diseases: Focus on cell type differences.
Fujigaki H; Yamamoto Y; Saito K
Neuropharmacology; 2017 Jan; 112(Pt B):264-274. PubMed ID: 26767951
[TBL] [Abstract][Full Text] [Related]
9. Drosophila eye color mutants as therapeutic tools for Huntington disease.
Green EW; Campesan S; Breda C; Sathyasaikumar KV; Muchowski PJ; Schwarcz R; Kyriacou CP; Giorgini F
Fly (Austin); 2012; 6(2):117-20. PubMed ID: 22634544
[TBL] [Abstract][Full Text] [Related]
10. Galantamine-Memantine Combination and Kynurenine Pathway Enzyme Inhibitors in the Treatment of Neuropsychiatric Disorders.
Bai MY; Lovejoy DB; Guillemin GJ; Kozak R; Stone TW; Koola MM
Complex Psychiatry; 2021 Aug; 7(1-2):19-33. PubMed ID: 35141700
[TBL] [Abstract][Full Text] [Related]
11. Abnormal kynurenine pathway of tryptophan catabolism in cardiovascular diseases.
Song P; Ramprasath T; Wang H; Zou MH
Cell Mol Life Sci; 2017 Aug; 74(16):2899-2916. PubMed ID: 28314892
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of kynurenine pathway metabolism in Toxoplasma gondii-infected mice: implications for schizophrenia.
Notarangelo FM; Wilson EH; Horning KJ; Thomas MA; Harris TH; Fang Q; Hunter CA; Schwarcz R
Schizophr Res; 2014 Jan; 152(1):261-7. PubMed ID: 24345671
[TBL] [Abstract][Full Text] [Related]
13. Endogenous kynurenate controls the vulnerability of striatal neurons to quinolinate: Implications for Huntington's disease.
Sapko MT; Guidetti P; Yu P; Tagle DA; Pellicciari R; Schwarcz R
Exp Neurol; 2006 Jan; 197(1):31-40. PubMed ID: 16099455
[TBL] [Abstract][Full Text] [Related]
14. Targeted deletion of kynurenine 3-monooxygenase in mice: a new tool for studying kynurenine pathway metabolism in periphery and brain.
Giorgini F; Huang SY; Sathyasaikumar KV; Notarangelo FM; Thomas MA; Tararina M; Wu HQ; Schwarcz R; Muchowski PJ
J Biol Chem; 2013 Dec; 288(51):36554-66. PubMed ID: 24189070
[TBL] [Abstract][Full Text] [Related]
15. Impaired kynurenine pathway metabolism in the prefrontal cortex of individuals with schizophrenia.
Sathyasaikumar KV; Stachowski EK; Wonodi I; Roberts RC; Rassoulpour A; McMahon RP; Schwarcz R
Schizophr Bull; 2011 Nov; 37(6):1147-56. PubMed ID: 21036897
[TBL] [Abstract][Full Text] [Related]
16. Kynurenine 3-mono-oxygenase inhibitors attenuate post-ischemic neuronal death in organotypic hippocampal slice cultures.
Carpenedo R; Meli E; Peruginelli F; Pellegrini-Giampietro DE; Moroni F
J Neurochem; 2002 Sep; 82(6):1465-71. PubMed ID: 12354294
[TBL] [Abstract][Full Text] [Related]
17. Metabolism of [5-3H]kynurenine in the rat brain in vivo: evidence for the existence of a functional kynurenine pathway.
Guidetti P; Eastman CL; Schwarcz R
J Neurochem; 1995 Dec; 65(6):2621-32. PubMed ID: 7595559
[TBL] [Abstract][Full Text] [Related]
18. A systemically-available kynurenine aminotransferase II (KAT II) inhibitor restores nicotine-evoked glutamatergic activity in the cortex of rats.
Koshy Cherian A; Gritton H; Johnson DE; Young D; Kozak R; Sarter M
Neuropharmacology; 2014 Jul; 82():41-8. PubMed ID: 24647121
[TBL] [Abstract][Full Text] [Related]
19. Xanthurenic Acid Formation from 3-Hydroxykynurenine in the Mammalian Brain: Neurochemical Characterization and Physiological Effects.
Sathyasaikumar KV; Tararina M; Wu HQ; Neale SA; Weisz F; Salt TE; Schwarcz R
Neuroscience; 2017 Dec; 367():85-97. PubMed ID: 29031603
[TBL] [Abstract][Full Text] [Related]
20. The Kynurenine Pathway and Kynurenine 3-Monooxygenase Inhibitors.
Hughes TD; Güner OF; Iradukunda EC; Phillips RS; Bowen JP
Molecules; 2022 Jan; 27(1):. PubMed ID: 35011505
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
